US Patent

US12083182 — Controlled-release CNP agonists with increased NEP stability

Method of Use · Assigned to Ascendis Pharma Growth Disorders AS · Expires 2037-01-05 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects controlled-release CNP agonists with increased NEP stability and their use in pharmaceutical compositions for treatment methods.

USPTO Abstract

The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4425`	—
`U-4425`	—
`U-4425`	—

Patent Metadata

Patent number: US12083182
Jurisdiction: US
Classification: Method of Use
Expires: 2037-01-05
Drug substance claim: No
Drug product claim: No
Assignee: Ascendis Pharma Growth Disorders AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.